key: cord-0915908-w6j5ryna
authors: Vietzen, Hannes; Danklmaier, Vera; Zoufaly, Alexander; Puchhammer-Stöckl, Elisabeth
title: High-affinity FcγRIIIa genetic variants and potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe COVID-19
date: 2022-04-30
journal: Genet Med
DOI: 10.1016/j.gim.2022.04.005
sha: e1eb7d1dd115ab2f9154576009350aef85280409
doc_id: 915908
cord_uid: w6j5ryna

PURPOSE: Host genetic variants in activating natural killer (NK) cell receptors may contribute to differences in severity of COVID-19. NK cell-mediated antibody-mediated cellular cytotoxicity (ADCC) responses play, however, a controversial role in SARS-CoV-2 infections. It is unclear whether proinflammatory and cytotoxic SARS-CoV-2-specific ADCC responses limit disease severity or rather contribute to the immunopathogenesis of severe COVID-19. METHODS: Using a genetic association approach and subsequent in vitro antibody-dependent NK cell activation experiments, we investigated whether genetic variants in the FcγRIIIa-encoding FCGR3A gene, resulting in expression of either a low-affinity or high-affinity variant, and individual SARS-CoV-2-specific ADCC response contribute to COVID-19 severity. RESULTS: In our study, we showed that the high-affinity variant of the FcγRIIIa receptor, 158-V/V, is significantly over-represented in hospitalized and deceased patients with COVID-19, whereas the low-affinity FcγRIIIa-158-F/F variant occurs more frequently in patients with mild COVID-19 (P < .0001). Furthermore, functional SARS-CoV-2 antibody-specific NK cell-mediated ADCC assays revealed that significantly higher proinflammatory ADCC responses occur in hospitalized patients with COVID-19, and are especially observed in NK cells expressing the FcγRIIIa-158-V/V variant (P < .0001). CONCLUSION: Our study provides evidence that pronounced SARS-CoV-2-specific NK cell-mediated ADCC responses are influenced by NK cell FcγRIIIa genetic variants and are a hallmark of severe COVID-19.

Since the first emergence in 2019, SARS-CoV-2 and associated COVID-19 have caused a global, ongoing pandemic. Most infections results in mild or moderate respiratory symptoms, but some patients experience severe disease, often including an acute respiratory distress syndrome. 1 Severe COVID-19 is often associated with hypercytokinemia, which is hallmarked by elevated plasma levels of, among others, TNFα. 2, 3 Different risk factors such as patients' age and cardiovascular as well as respiratory comorbidities are associated with progression to severe COVID-19. 4 However, increasing number of studies also indicate that host genetic factors might substantially contribute to the development of severe COVID-19 in individual patients. 5 Natural killer (NK) cells are cytotoxic lymphocytes that link SARS-CoV-2-specific innate and adaptive immune responses. NK cells recognize the IgG antibodies opsonizing SARS-CoV-2-infected cells and cell-free virions via the Fcγ-receptor FcγRIIIa/CD16a. This antibody-receptor interaction leads subsequently to the release of proinflammatory cytokines, such as interferon gamma (IFNγ) and TNFα, as well as of cytolytic mediators, such as perforin and granzyme B, which cause antibody-mediated cellular cytotoxicity (ADCC). The FcγRIIIa receptor may be present in 3 variants, depending on a genetic single-nucleotide variation (SNV, formerly single-nucleotide polymorphism [SNP] ), rs396991, in FcγRIIIa-encoding FCGR3A gene (NM_000569.8:c.526T>G). This results in expression of either the low-affinity phenylalanine (F), the high-affinity valine (V), or the heterozygous codominant expression of both alleles at amino acid position 158. 6 Overall, NK cells play a controversial role in patients with COVID-19. Several in vitro and genetic association studies showed that an early SARS-CoV-2-specific NK cell response may be beneficial for the patients, because it may inhibit viral dissemination and prevent severe COVID-19. 7, 8 In contrast, other ex vivo studies found that highly activated NK cells occur in severely diseased patients with COVID-19, which could indicate that NK cell effector functions may contribute to COVID-19 progression. 9 So far, only few data are available especially on SARS-CoV-2-specific and NK cell-mediated ADCC responses in patients with COVID-19. Therefore we aimed to clarify, whether the overall SARS-CoV-2-specific ADCC responses contribute to the disease severity in patients with COVID-19.

In total, 197 Austrian White patients with COVID-19 (41.2% female, median age: 59.2), who were confirmed SARS-CoV-2 positive using polymerase chain reaction (PCR) 10 from respiratory swabs between March 6, 2020 and July 24, 2020, at Center for Virology, Medical University of Vienna, were included in the study. All patients were infected with the SARS-CoV-2 wild type of European lineage, which was the dominant strain at that time in Austria. Of all patients, 46 (23.4%) showed only mild symptoms and stayed in home isolation (nonhospitalized), whereas 151 (76.6%) patients with COVID-19 required hospitalization (hospitalized). In addition, we included 99 healthy White Austrian individuals who were SARS-CoV-2 PCR-negative and without any COVID-19 symptoms as controls, who were selected according to age of the hospitalized patients with COVID-19.

From our study cohort, sequential plasma samples of 19 hospitalized patients with COVID-19 (26.3% female, median age: 64.3) were collected for 27 days after symptoms onset in 3-day intervals. In addition, 10 patients with mild COVID-19 (60% female, median age: 39.7) were included in the ADCC assays. From the nonhospitalized patients, 1 plasma sample for each patient was collected between 28 and 31 days after disease onset.

In addition, 6 plasma samples from healthy patients, who were SARS-CoV-2 seronegative, obtained during the period 2014-2018 for routine vaccination titer controls, were included in the study.

We included 26 voluntary and healthy blood donors in our study from whom CD56 + CD16 + NK cells were isolated for ADCC assays. Peripheral blood mononuclear cells were first isolated using Ficoll density gradient centrifugation from buffy coats (Austrian Red Cross). The CD56 + CD16 + NK cell subset was then enriched via 2-step magnetic labeling using human CD56 + CD16 + NK Cell Isolation Kit (Miltenyi Biotec) according to the manufacturer's instruction. Cells were stored frozen at −80 • C in 4×10 6 viable CD56 + CD16 + NK cell aliquots in 90% fetal calf serum + 10% dimethyl sulfoxide (both Sigma Aldrich).

Viral RNA was isolated from the respiratory swabs of patients with COVID-19 using NucliSens EasyMag extractor (BioMérieux). SARS-CoV-2 RNA was eluted in 50 μl nuclease-free water. SARS-CoV-2 RNA was quantified using a recently published quantitative PCR. 10 

SARS-CoV-2 S1-domain-specific IgG antibodies were detected and quantified using enzyme-linked immunosorbent assay (Euroimmun).

Genomic DNA was isolated from the respiratory swabs or plasma from patients with COVID-19, controls, and NK cell donors using NucliSens EasyMag extractor. Genomic DNA was eluted in 50 μl nuclease-free water, followed by determination of the FcγRIIIa-158-F/V (NM_000569.8:c.526T>G) SNV through genotyping using nested PCR and Sanger sequencing according to a published protocol. 11 Primers and HotStarTaq Master Mix (Qiagen) were used on a MiniAmp ThermoCycler (Applied Biosystems). PCR amplicons from nested PCR were visualized on a 3% agarose gel (Serva) containing 0.1% Midori Green Advance DNA stain (Nippon Genetics). The PCR products were cleaned using the ExoSAP-IT PCR Product Cleanup Reagent (Thermo Fisher Scientific) according to the manufacturer's instruction. The amplicons were subsequently sequenced using BigDye Terminator v1.1 Cycle Sequencing Kit (Thermo Fisher Scientific) and 3130 Genetic Analyzer (Applied Biosystems). Sequences were analyzed using Geneious Prime 2019 software (Biomatters).

For SARS-CoV-2-specific and NK cell-mediated ADCC assays, NK cells were thawed and preactivated overnight in RPMI medium supplemented with 10% fetal calf serum, 1% L-glutamine (all: Thermo Fisher Scientific), 10 ng/ml IL-12 (PeproTec) and 100 ng/ml IL-18 (Biozym Scientific). After 16 hours, CD56 + CD16 + NK cells were harvested through centrifugation at 400g for 5 minutes and washed once with Opti-MEM I Reduced Serum Medium (Gibco, Fisher Scientific GmbH). A total of 5×10 5 CD56 + CD16 + NK cells were then resuspended in 960 μl Opti-MEM (Thermo Fisher Scientific) and transferred to a 24-well plate together with 30 μl of patient's plasma and 10 μl of diluted SARS-CoV-2 purified viral lysate (3 μg/ ml, isolate: USA-WA1/2020, Native Antigens). Then 5 μl of anti-human CD107a-PerCP (Becton Dickinson) was added and the suspension was incubated for 6 hours at 37 • C. After 1 hour, monensin and brefeldin A (Biozym Scientific GmbH) were added at a concentration of 1 μl/ mL to inhibit protein transport from the endoplasmic reticulum to the Golgi apparatus. After incubation for additional 5 hours, cells were harvested, fixed, and permeabilized for flow cytometry using FIX & PERM Cell Fixation & Cell Permeabilization Kit (Thermo Fisher Scientific). The following fluorescently labeled antihuman monoclonal antibodies were used for cytometry: CD16-APC-H7, CD56-APC, IFNγ-PE-Cy7 (Becton Dickinson), TNFα-PE, and perforin-BV510 (both Biolegend). To distinguish between living and dead cells, LIVE/DEAD Fixable Green Dead Cell Stain Kit (Thermo Fisher Scientific) was further used according to the manufacturer's instruction. Cells were analyzed on a BD FACSCanto II flow cytometer (BD Biosciences) using BD FACSDiva Software (Version 6.1.1 and Version 9.0, BD Biosciences).

The χ 2 test and the Kruskal-Wallis test were used to compare the distribution of sex and age between controls and patient cohorts. Distribution of different FcγRIIIa variants between the patient groups with COVID-19 and the control cohort were compared using the χ 2 or F test.

Outliers in the flow cytometry data were identified using the robust regression and outlier removal method. Statistical differences between nonhospitalized and hospitalized patients with COVID-19 were calculated for each time point using analysis of variance or t test. ADCC inducing plasma samples from hospitalized and nonhospitalized patients with COVID-19 were identified using 6 healthy control individuals who were SARS-CoV-2 seronegative and a 95% CI as described by Frey et al. 12 Correlation of individual ADCC responses with viral load as well as SARS-CoV-2specific IgG antibody titers was assessed using Pearson correlation.

A P value of <.05 was considered statistically significant. Statistical differences were assessed using GraphPad Prism 9.

In total, 197 patients with COVID-19, who were infected with SARS-CoV-2 between March and July 2020, were included in the study. Of these, 46 (23.4%) patients showed only mild symptoms and stayed in home isolation (nonhospitalized), whereas 151 (76.6%) patients needed hospitalization (hospitalized). As shown in Table 1 , patients with COVID-19 requiring hospitalization were significantly older and more frequently had comorbidities than the nonhospitalized patients with COVID-19. We also included 99 healthy individuals who were SARS-CoV-2 PCR negative as controls.

We first evaluated the FcγRIIIa-158-V/F polymorphism in patients with COVID-19 and healthy controls ( Figure 1A ). Mildly ill patients with COVID-19 encoded significantly more often for low-affinity FcγRIIIa-158-F/F genotype, whereas the homozygous high-affinity FcγRIIIa-158-V/V (P = .0007, odds ratio [OR] = 6.7, F test) but not the heterozygous FcγRIIIa-158-F/V (P = .26, OR = 2.3, F test) variant was more frequent in hospitalized patients ( Figure 1A ). Compared with healthy SARS-CoV-2 negative controls, nonhospitalized patients with COVID-19 showed a significantly higher frequency of the FcγRIIIa-158-F/F genotype, whereas the FcγRIIIa-158-F/V and FcγRIIIa-158-F/ F genotypes occurred more frequently in controls (P = .004, OR = 2.86, F test). No significant differences were however found in the distribution of the FcγRIIIa-158-F/V variants between hospitalized patients with COVID-19 and healthy controls ( Figure 1A ).

Of all hospitalized patients, 34 (22.5%) died of COVID-19 during hospitalization. Deceased patients were significantly older than survivors (Table 1 ) and, as shown in Figure 1B , death occurred significantly more often in patients encoding for FcγRIIIa-158-V/V, than in those encoding the

We found, however, no significant differences in distribution of the heterozygous FcγRIIIa-158-F/V variant with regard to survival (P = not significant [ns], F test).

Of all hospitalized patients with COVID-19, 40 were treated for severe disease on intensive care units (ICUs) according to the defined standards (https://www.covid1 9treatmentguidelines.nih.gov).

Hospitalized patients requiring ICU treatment and hospitalized non-ICU patients showed no significant differences with regard to their age and sex. Compared with hospitalized non-ICU patients, the FcγRIIIa-158-F/F variant was especially rare in ICU patients, whereas the FcγRIIIa-158-V/V variant occurred significantly more frequently in these patients (P = .04, OR = 3.5, F test, Supplementary Figure 1 ).

Because patient's age and sex pose significant risk for the development of severe COVID-19, 4 we compared the distribution of FcγRIIIa-158-V/F variants between sex and age groups. As shown in Supplemental Table 1 , FcγRIIIa-158-V/F variants were equally distributed between the sexes, whereas a significantly higher frequency of FcγRIIIa-158-V/ V variant was present in the younger age group consisting of patients aged <60 years. We observed however no significant differences between nonhospitalized patients aged <60 years and >60 years (P = ns, χ 2 test) or hospitalized patients aged <60 years and >60 years (P = ns, χ 2 test).

We then also compared the distribution of FcγRIIIa-158-V/F variants between surviving and deceased patients with COVID-19 as well as between age groups. As shown in Supplemental Table 2 , FcγRIIIa-158-V/V variant was significantly overrepresented in deceased patients in patients aged >60 and <60 years (Supplemental Table 2 ).

We then further analyzed, on functional basis, whether and to what extent there is difference between the SARS-CoV-2specific and NK cell-mediated ADCC responses in hospitalized patients with COVID-19 and nonhospitalized patients with COVID-19. Therefore, we selected all hospitalized patients with COVID-19 of our cohort, from whom plasma samples were available in 3 (±1)-day intervals after the onset of clinical symptoms (n = 19, 12.6%) as well as all mildly ill patients with samples available between 28 and 31 days after the disease onset (n = 9, 19.6%). To test the kinetics of the SARS-CoV-2-specific ADCC response, we isolated CD56 + CD16 + NK cells from 26 healthy blood donors and stimulated each of these NK cell preparations with SARS-CoV-2 lysate and tested the effect of each plasma samples of patients with COVID-19 on all NK cell preparations, respectively. In addition, similarly we tested the plasma of 6 healthy control individuals who were SARS-CoV-2 seronegative with all NK cell preparations. We subsequently analyzed the expression of cytotoxicity markers, CD107a and perforin, as well as the expression of proinflammatory cytokines IFNγ and TNFα of CD56 + CD16 + NK cells using flow cytometry (Supplemental Figures 2 and 3) .

As shown in Figure 2A to D and Supplemental Figure 4 , a detectable SARS-CoV-2-specific ADCC response developed in all hospitalized patients with COVID-19 after the disease onset. Overall, expression of perforin and IFNγ in the plasma of patients with COVID-19 exceeded that of healthy persons, who were SARS-CoV-2 seronegative, starting from 6 ± 1 days after start of symptoms, whereas CD107a and TNFα expression increased significantly 9 ± 1 days after symptom onset. For all ADCC markers, we observed an overall increase in SARS-CoV-2-specific NK cell-mediated ADCC response, which peaked around 21 days after symptom onset.

In patients with COVID-19 with mild SARS-CoV-2 infections, we identified an overall weaker or even absent SARS-CoV-2-specific ADCC response 28 to 31 days after symptom onset (Figure 2A-D) . Only 4 of 9 (44.4%) nonhospitalized mildly ill patients with COVID-19 showed an NK cell-mediated SARS-CoV-2-specific ADCC response for all tested markers.

We then also evaluated whether the SARS-CoV-2specific ADCC response depended on maximal viral load found in individual hospitalized patients. Therefore, we correlated the individual highest viral load (median: 3.4 log 10 copies/mL, 1.5-6.9 log 10 copies/mL) with the highest ADCC responses, reflected by the individuals' highest percentage of CD107a, perforin, IFNγ, or TNFα-expressing CD56 + CD16 + NK cells. We found no significant correlation between maximal viral load and the maximal ADCC responses (all: P = ns, Spearman test).

We further evaluated, whether a strong SARS-CoV-2specific ADCC response is reflected by high SARS-CoV-2 S1-domain-specific IgG antibody titers. Therefore, we correlated individual percentage of CD107a, perforin, IFNγ, or TNFα-expressing CD56 + CD16 + NK cells and SARS-CoV-2-specific IgG antibody titers in hospitalized patients with COVID-19 for each time point. We did not find significant correlation between SARS-CoV-2 S1-domain-specific IgG antibody titers and respective ADCC responses for any timepoint (all: P = ns, Spearman test). We then also analyzed the samples of all nonhospitalized patients, in whom SARS-CoV-2-specific ADCC responses were detectable (4/9, 44.4%), for ADCC cytotoxicity and inflammatory cytokine markers according to the FcγRIIIa-158-V/F variants of NK cell donors. Plasma samples from patients with COVID-19 with mild infections led to a significantly lower expression of activation markers, except for perforin, in CD56 + CD16 + NK cells expressing FcγRIIIa-158-F/F variant, than those expressing FcγRIIIa-158-V/V or FcγRIIIa-158-V/F variants. Differences between the activation levels of CD56 + CD16 + NK cells encoding for FcγRIIIa-158-V/V and those encoding for heterozygous FcγRIIIa-158-V/F variants were, however, not statistically significant ( Figure 3A-H) .

The role of antibody-mediated activation of NK cells in patients with COVID-19 has not been fully clarified so far, and it remains controversial whether SARS-CoV-2-specific ADCC responses increase COVID-19 severity or contribute to limitation of the disease. 8, 13, 14 In this study, we now provide evidence that the SARS-CoV-2-specific antibodymediated activation of NK cells in patients with COVID-19 is dependent on individual expression of genetically distinct FcγRIIIa variants, and that an overall higher SARS-CoV-2-specific ADCC response is associated with development of severe COVID-19.

In our study cohort, the FcγRIIIa-158-F/F variant was significantly less prevalent in hospitalized patients with COVID-19 and especially in patients with COVID-19 dying from SARS-CoV-2 infection than in nonhospitalized patients with mild infections. In contrast, a significantly higher proportion of patients expressing the FcγRIIIa-158-V/V receptor variant was hospitalized and died from COVID-19. Further in vitro experiments subsequently showed on a functional basis that the stimulation with SARS-CoV-2specific antibodies leads to a significantly higher activation of NK cells with FcγRIIIa receptors carrying a 158-V amino acid residue than the NK cells carrying the homozygous FcγRIIIa-158-F/F variant. An earlier in vitro study showed that, in general, the FcγRIIIa-158-V/V variant provides a significantly increased affinity to the Fc-part of IgG antibodies compared with the FcγRIIIa-158-F/F receptor variant. 6 Our data are in agreement with this observation.

In addition, we showed that higher activation of NK cells carrying the FcγRIIIa-158-V/V variant may contribute to a severe clinical course of COVID-19. This may be because of the fact that, as our data reveal, FcγRIIIa-158-V/V expressing NK cells show higher expression levels of the proinflammatory cytokines TNFα and IFNγ. Especially TNFα was recently identified as a marker cytokine for hypercytokinemia in patients with severe COVID-19. 2 In addition, TNFα and IFNγ are key factors in the pathogenesis of severe COVID-19, because especially TNFα is a potent chemoattractant for leukocytes and promote the expression of adhesion molecules on endothelial cells, thereby providing the functional basis for migration of leukocytes into the SARS-CoV-2-infected lung. Using a SARS-CoV-2 mouse model, others recently found that the combination of both TNFα and IFNγ induced inflammatory cell death and a lethal hypercytokinemia. 15 The high potential of NK cell based immunological mechanisms, such as ADCC in the lung, is further underlined by other authors who showed overall decreased NK cell levels in the peripheral blood of severely diseased patients with COVID-19, and consequently hypothesized that NK cells migrate into the SARS-CoV-2-infected lung during severe infection. 16 It seems thus likely that NK cells are an important source of TNFα and IFNγ in patients with COVID-19, and that NK cell-driven ADCC contributes, through these effectors, substantially to the course of COVID-19. These effects are, as we showed, to some extent dependent on the individual FcγRIIIa-158-V/F variant of the patients and may be is the one factor contributing to the individually different clinical severity of COVID-19. We also found that NK cells that were stimulated with plasma from severely diseased patients with COVID-19 showed markedly increased activation levels of cytotoxicity markers compared with that from patients with COVID-19 with mild disease. This is in agreement with recently published ex vivo studies that found a higher NK cell activation status in severe than in mild COVID-19, which was hallmarked by the high-level expression of perforin and evidenced a status of NK cell exhaustion. 9, 17 Another ex vivo study analyzed the potential of peripheral blood mononuclear cells derived from patients with COVID-19 to induce an ADCC response against rituximabcoated Raji cells. 18 The authors found a considerably defective ADCC response in hospitalized patients with COVID-19, which also shows exhaustion of ADCC mediating cells in these patients. Combined, these and our data show that the SARS-CoV-2-specific antibody-mediated ADCC responses may contribute to the immune exhaustion in patients with COVID-19. These findings are of special interest because the immune exhaustion in convalescent patients with COVID-19 was recently proposed as a potential risk factor for "long-COVID," a multisymptomatic condition characterized by long-term sequelae appearing after the convalescence period of COVID-19. 19 In our study, the frequency of FcγRIIIa-158-V/F variants in control patients was comparable to recently published European study cohorts. 20 Whereas the FcγRIIIa-158-F/F and FcγRIIIa-158-V/F variants occur frequently, the high-affinity FcγRIIIa-158-V/V genotype occurs more rarely and was observed in our cohort in only 15% of control persons. It was described that the FcγRIIIa-158-V/ V genotype occurs somewhat more frequently in individuals of African American ancestry. 21, 22 Interestingly, recently published studies in British patients with COVID-19 identified Afro-American ancestry as an independent risk factor for severe disease and death due to COVID-19. 23 It requires, however, further studies to analyze to what extent genetic risk factors and especially the FcγRIIIa-158-V/F variants may contribute to the increased risk for severe COVID-19 in patients of distinct ethnic backgrounds.

In our study, we identified FcγRIIIa-158-V/V variant as an independent risk factor for severe COVID-19, especially in patients aged <60 years. This finding may be associated with the pronounced shaping of NK cell repertoire by aging. In elderly, higher frequencies of the CD56 dim CD16 + NK cells are detectable than in younger individuals, who show higher levels of CD56 bright CD16 + NK cells. 24 Although CD56 dim CD16 + NK cells are highly cytotoxic, CD56 bright CD16 + cells have a specialized role as abundant cytokine producers. 25 It is thus reasonable that FcγRIIIa-158-V/V variant is an especially important risk factor for severe COVID-19 in younger individuals, because highlevels of CD56 bright CD16 + cells may contribute to patients' hypercytokinemia.

From this study it became apparent that the SARS-CoV-2-specific ADCC response is unlikely to contribute to an early defense against SARS-CoV-2, because patients with COVID-19 developed a detectable SARS-CoV-2specific and NK cell-mediated ADCC response only starting from day 6 after the first onset of clinical symptoms. A previous study in Chinese patients with COVID-19, similarly showed that the overall increase in SARS-CoV-2-specific ADCC response in patients with COVID-19 peaked around 11 to 20 days after disease onset. 8 This is different to other NK cell-driven responses, as we recently showed that early and potent NKG2C + NK cell responses may prevent the development of severe COVID-19. 7 Although we focused on the association between patients' FcγRIIIa-158-V/F receptor variants and the extent of ADCC, others have analyzed individual antibody profile in ADCC and found a positive correlation between receptor binding domain-specific ADCC response and higher levels of inflammation and immune activation markers, including TNFα. 13 In further studies, a combined evaluation of the individual antibody response and the NK cell FcγRIIIa-158-V/F receptor polymorphism of single patients may allow for judging more precisely a patients' risk for severe COVID-19 infections. As a further limitation, we focused in our study only on the dynamics and extent of the NK cell-mediated ADCC responses. Notably, FcγRIIIa is not only expressed on NK cells, but also to a lower extent on monocytes, macrophages, and neutrophils. 26, 27 The migration and high-level activation of monocytes, macrophages, and especially neutrophils was recently associated with severe progression of COVID-19. 28, 29 Further studies are therefore required to evaluate the ADCC response in FcγRIIIa-expressing cells beyond NK cell response.

In our study cohort, FcγRIIIa-158-F/F genotype was only overrepresented in nonhospitalized mildly diseased patients with COVID-19, whereas severely diseased hospitalized patients with COVID-19 and healthy controls showed a similar distribution of the FcγRIIIa-158-F/V variants. These results show that FcγRIIIa-158-F/F individuals have a lower risk for severe COVID-19. Our results are of special interest as potential predictive markers for the COVID-19 disease severity are still scare. Further studies, also in prospective study cohorts, are however needed to further assess to what extent FcγRIIIa-158-F/F individuals are protected from severe COVID-19.

In conclusion, we show that a potent SARS-CoV-2specific ADCC response is associated with the development of severe COVID-19 and that the FcγRIIIa-158-V/F polymorphism significantly contributes to the antibodymediated activation of NK cell against SARS-CoV-2. Further studies are needed to evaluate the fine specificity of the ADCC responses against SARS-CoV-2 and to gain further insights into the impact ADCC has on the immune pathogenesis of COVID-19.

De-identified data are available upon request by contacting the corresponding author (hannes.vietzen@meduniwien. ac.at).

Acute respiratory distress syndrome

An inflammatory cytokine signature predicts COVID-19 severity and survival

Pathogenesis of COVID-19-induced ARDS: implications for an ageing population

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Update on human genetic susceptibility to COVID-19: susceptibility to virus and response

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype

Puchhammer-Stöckl E. Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19

Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients

Natural killer cell immunotypes related to COVID-19 disease severity

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Accurate interrogation of FCGR3A rs396991 in European and Asian populations using a widely available TaqMan genotyping method

A statistically defined endpoint titer determination method for immunoassays

COVID-19 severity is associated with differential antibody Fc-mediated innate immune functions. mBio

Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma

Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes

Immunological and inflammatory profiles in mild and severe cases of COVID-19

Hallmarks of immune response in COVID-19: exploring dysregulation and exhaustion

Impaired antibodydependent cellular cytotoxicity in a Spanish cohort of patients with COVID-19 admitted to the ICU

Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection

FcgammaRIIIA-158V and rheumatoid arthritis: a confirmation study

Fcγ receptor IIIa singlenucleotide polymorphisms and haplotypes affect human IgG binding and are associated with lupus nephritis in African Americans

Association of rheumatoid factor production with FcgammaRIIIa polymorphism in Taiwanese rheumatoid arthritis

Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform

Shaping of NK cell subsets by aging

CD56bright natural killer (NK) cells: an important NK cell subset

Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation

CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes

Monocytes and macrophages in COVID-19. Front Immunol

Neutrophils in COVID-19

The study was funded by the Center for Virology, Medical University of Vienna, Vienna, Austria.

The authors declare no conflicts of interest.

The online version of this article (https://doi.org/10.1016/j. gim.2022.04.005) contains supplementary material, which is available to authorized users.

The study was approved by the institutional review board of the Medical University of Vienna (EK No. 1881/2020). According to the review board, no informed consent was required from the patients, because only leftover and stored samples from routine laboratory diagnosis were used in the retrospective study.